Contact: [email protected]
| Title | Tumor type | Line | Study information |
|---|---|---|---|
| HiPeRMESO | Malignant Pleural Mesothelioma | 1L | After induction chemotherapy + surgery (R0-R1); High-dose RT, Lungsparing multimodality; DLCO > 40% |
| DOLBY-LC01 | NSCLC stage IV and healty subjects | <1L | Tissue, blood and urine collection prior to 1L patients, blood and urine collection for healthy subjects. |
| LONG 20-06 | NSCLC | 1L | Blood collection in inoperable/relapsed NSCLC starting ICI treatment; 1st collection before start therapy |
| JZJX | NSCLC stage IB-IIIA, RET fusion | 1L | Selpercatinib vs placebo following definitive locoregional therapy; RET fusion on PCR/NGS |
| PACIFIC-8 | NSCLC stage III | 1L maintenance | PD-L1 TC ≥ 1%; Durvalumab + domvanalimab following definitive platinum-based cCRT without progression |
| LUNG platform | NSCLC stage III-IV, PD-L1 high | 1L | Pembrolizumab vs. dostarlimab vs. dostarlimab + belrestotug vs. dostartlimab + belrestotug + GSK6097608; PD-L1 high (TC/TPS ≥ 50%); former or current smoker (>100 cigarettes in lifetime) |
| KRYSTAL-7 | NSCLC stage IIIB-IV, KRAS G12C | 1L | MRTX849 +/- pembrolizumab; unresectable or metastatic |
| TeliMET (NSCLC-01) | NSCLC stage III-IV | >1L | Telisotuzumab vedotin vs. docetaxel; c-Met overexpression, EGFR wt |
| DDRiver (NSCLC 322) | NSCLC stage III-IV | >1L | M1774 (ATR inhibitor) + cemiplimab; after prior anti-PD-(L)1 and platinum-based therapy |
| Be6A LUNG-01 | NSCLC stage IIIb-IV | >1L | SGN-B6A vs. docetaxel; non-squamous |
| SAFFRON | NSCLC stage III-IV, EGFRm | 2-3L | Savolitinib + osimertinib vs. platinum-based doublet CT; EGFRm; MET overexpression/amplified; after progression osimertinib |
| PRIMALung | SCLC limited – extensive stage | after 1L | PRophylactic cerebral Irradiation or active MAgnetic resonance imaging surveillance in SCLC (stage I-IV) |
| LAGOON | SCLC limited – extensive stage | 2L | Lurbinectedin + irinotecan vs. topotecan/irinotecan |